Microcap Movers for Wednesday November 30, 2011

Below are highlights from Benzinga's daily coverage of microcap securities. Benzinga provides comprehensive, objective, and conflict-free coverage of the microcap sector in real-time at

.

Shares of GLG Life Tech corp

the Vancouver, BC manufacturer of stevia, a zero-calorie, natural sweetener, rose 48% Wednesday, after the company announced the signing of a renewable five-year product supply agreement with International Flavors & Fragrances Inc.

for high-purity Rebaudioside C extracts. Mark Dewis, Vice President R&D, Flavors for IFF, said, "Commercialization of Reb C marks another step forward in the evolution and development of IFF flavor solutions. This technology will play an important role in supporting healthy and great-tasting flavors for our customers. I am delighted with the dedicated efforts of GLG and IFF in the commercialization of this technology and look forward to making it a success." GLG Life Tech traded Wednesday in a range of $0.88 to $1.26 and closed at $1.14, on 7 times the average daily volume.

Adeona Pharmaceuticals

, the Ann Arbor, MI pharmaceutical company focused on the development of drug product candidates to treat serious illnesses, rose 16% Wednesday after the company announced that their clinical collaborator for amyotrophic lateral sclerosis, PNA Center for Neurological Research, reported top-line results from its pilot Phase I/II open label, three month safety study of oral high dose zinc therapy in ALS, also known as Lou Gehrig's disease. The clinical study met its primary outcome as no safety issues related to zinc therapy were observed. In addition, an average decrease in the monthly rate of disease progression was observed in the ALS patients on zinc therapy, compared to published historical controls, as well as compared to the average monthly rate of disease progression of the subjects prior to enrollment in the study. Adeona shares traded Wednesday in a range of $0.89 to $1.14 and closed at $0.97, on 19 times the average daily volume.

Shares of Genetic Technologies

the Fitzroy, Australia genetic testing company, rose 19% Wednesday as Ladenburg Thalmann analyst Kevin DeGeeter initiated coverage on the company with a Buy rating and $7.50 price target. DeGeeter noted in his report: "Following the rapid expansion of molecular diagnostic products over the past five years, in our view, the sector suffers from a glut of content but a limited supply of companies with commercial infrastructure and regulatory expertise. In this environment we believe Genetic Technologies' strategy of acquiring and repositioning tests offers a more attractive return than internal development." Genetic Technologies traded in a range of $3.41 to $4.20 Wednesday on 60% higher than average daily volume, and closed at $3.87. To get information like this on a streaming basis during the trading day, try a 100% free trial to

.